Rhythm versus rate control for atrial fibrillation in heart failure with preserved ejection fraction. 2022

Mohammed Al-Sadawi, and Saadat Aleem, and Faisal Aslam, and Robin Jacobs, and Gregg Stevens, and Ibrahim Almasry, and Abhijeet Singh, and Roger Fan, and Eric Rashba
Stony Brook Heart Institute, Stony Brook Medicine, Stony Brook, New York.

There are few prospective studies assessing the benefits of rhythm control of atrial fibrillation (AF) in patients with heart failure and preserved ejection fraction (HFpEF), which accounts for 50% of all heart failure patients. Conduct a meta-analysis to assess the effects of rhythm control (ablation and/or antiarrhythmic medications) vs rate control on all-cause mortality in AF patients with HFpEF. Databases were searched for studies reporting the effect of rhythm control vs rate control on mortality in patients with HFpEF (Ovid MEDLINE, EMBASE, Scopus, Web of Science, Google Scholar, and EBSCO CINAHL). The search was not restricted to time or publication status. The primary endpoint was all-cause mortality. The minimum duration of follow-up required for inclusion was 1 year. The literature search identified 1210 candidate studies; 5 studies and 16,825 patients were included. The study population had 57% men with a mean age of 71± 2.5 years. Rhythm control for AF was associated with lower all-cause mortality (odds ratio 0.735, 95% confidence interval 0.665-0.813; P < .001) as compared to rate control. Rhythm control for AF in patients with HFpEF was associated with decreased all-cause mortality.

UI MeSH Term Description Entries

Related Publications

Mohammed Al-Sadawi, and Saadat Aleem, and Faisal Aslam, and Robin Jacobs, and Gregg Stevens, and Ibrahim Almasry, and Abhijeet Singh, and Roger Fan, and Eric Rashba
December 2019, Journal of the American Heart Association,
Mohammed Al-Sadawi, and Saadat Aleem, and Faisal Aslam, and Robin Jacobs, and Gregg Stevens, and Ibrahim Almasry, and Abhijeet Singh, and Roger Fan, and Eric Rashba
April 2019, European journal of heart failure,
Mohammed Al-Sadawi, and Saadat Aleem, and Faisal Aslam, and Robin Jacobs, and Gregg Stevens, and Ibrahim Almasry, and Abhijeet Singh, and Roger Fan, and Eric Rashba
July 2020, Current cardiology reports,
Mohammed Al-Sadawi, and Saadat Aleem, and Faisal Aslam, and Robin Jacobs, and Gregg Stevens, and Ibrahim Almasry, and Abhijeet Singh, and Roger Fan, and Eric Rashba
January 2022, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese,
Mohammed Al-Sadawi, and Saadat Aleem, and Faisal Aslam, and Robin Jacobs, and Gregg Stevens, and Ibrahim Almasry, and Abhijeet Singh, and Roger Fan, and Eric Rashba
April 2019, European journal of heart failure,
Mohammed Al-Sadawi, and Saadat Aleem, and Faisal Aslam, and Robin Jacobs, and Gregg Stevens, and Ibrahim Almasry, and Abhijeet Singh, and Roger Fan, and Eric Rashba
January 2023, Frontiers in cardiovascular medicine,
Mohammed Al-Sadawi, and Saadat Aleem, and Faisal Aslam, and Robin Jacobs, and Gregg Stevens, and Ibrahim Almasry, and Abhijeet Singh, and Roger Fan, and Eric Rashba
May 2020, Current opinion in cardiology,
Mohammed Al-Sadawi, and Saadat Aleem, and Faisal Aslam, and Robin Jacobs, and Gregg Stevens, and Ibrahim Almasry, and Abhijeet Singh, and Roger Fan, and Eric Rashba
June 2008, The New England journal of medicine,
Mohammed Al-Sadawi, and Saadat Aleem, and Faisal Aslam, and Robin Jacobs, and Gregg Stevens, and Ibrahim Almasry, and Abhijeet Singh, and Roger Fan, and Eric Rashba
June 2023, JAMA,
Mohammed Al-Sadawi, and Saadat Aleem, and Faisal Aslam, and Robin Jacobs, and Gregg Stevens, and Ibrahim Almasry, and Abhijeet Singh, and Roger Fan, and Eric Rashba
June 2023, JAMA,
Copied contents to your clipboard!